Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
WB, F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Liver |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to aa 5 -23 of human Annexin VI. |
Lokalisation |
Cell Membrane |
Annexin VI
|
501-12384 |
1 ml |
- |
RUO |
polyclonal |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Liver |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to aa 5 -23 of human Annexin VI. |
Lokalisation |
Cell Membrane |
Annexin VI
|
501-12381 |
7 ml |
- |
RUO |
polyclonal |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Testis |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from C-terminus of human APAF-1 |
Lokalisation |
Cytoplasm |
Apaf 1 (CT) (Apoptosis Protease Activating Factor)
|
501-3952 |
0.5 ml |
- |
RUO |
polyclonal |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Testis |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from C-terminus of human APAF-1 |
Lokalisation |
Cytoplasm |
Apaf 1 (CT) (Apoptosis Protease Activating Factor)
|
501-3954 |
1 ml |
- |
RUO |
polyclonal |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Testis |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from C-terminus of human APAF-1 |
Lokalisation |
Cytoplasm |
Apaf 1 (CT) (Apoptosis Protease Activating Factor)
|
501-3951 |
7 ml |
- |
RUO |
polyclonal |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB, IP |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from C-terminus of human APC protein |
Lokalisation |
Cytoplasm |
APC (Adenomatous Polyposis Coli)
|
501-4084 |
1 ml |
- |
RUO |
polyclonal |
- |
Host |
Mouse |
Klon |
1/A5F6 |
Format |
Purified |
Methode |
F, P, EL, WB, IP |
Vorbehandlung |
Citrate |
Positivkontrolle |
Kidney |
Verdünnung |
1:500 - 1:1000 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide corresponding to amino acids 249-269 of rat aquaporin 1 |
Aquaporin 1
|
601-0278 |
100 µg (100 µl) |
- |
RUO |
1/A5F6 |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
BV, XE, PG, RB |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hepatocellular Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the N-terminus of human arginase-1 protein |
Lokalisation |
Cytoplasm, nucleus |
Arginase-1
|
501-19280 |
0.1 ml |
- |
RUO |
polyclonal |
- |
Host |
Rabbit |
Klon |
SP156 |
Format |
Concentrate |
Reaktivität |
BV,PG,RB |
Methode |
P |
Vorbehandlung |
EDTA |
Verdünnung |
1:100 |
Verdünnung |
Synthetic peptide derived from the C-terminus of human arginase-1 protein |
Arginase-1
|
501-4560 |
0.1 ml |
- |
RUO |
SP156 |
- |
Host |
Rabbit |
Klon |
EP261 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal human liver |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasma and nucleus |
Arginase-1
|
ACI3058A |
0.1 ml |
- |
CE/IVD |
EP261 |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
BV, XE, PG, RB |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hepatocellular Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the N-terminus of human arginase-1 protein |
Lokalisation |
Cytoplasm, nucleus |
Arginase-1
|
501-19282 |
0.5 ml |
- |
RUO |
polyclonal |
- |
Host |
Rabbit |
Klon |
SP156 |
Format |
Concentrate |
Reaktivität |
BV,PG,RB |
Methode |
P |
Vorbehandlung |
EDTA |
Verdünnung |
1:100 |
Verdünnung |
Synthetic peptide derived from the C-terminus of human arginase-1 protein |
Arginase-1
|
501-4562 |
0.5 ml |
- |
RUO |
SP156 |
- |
Host |
Rabbit |
Klon |
EP261 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal human liver |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasma and nucleus |
Arginase-1
|
ACI3058B |
0.5 ml |
- |
CE/IVD |
EP261 |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
BV, XE, PG, RB |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hepatocellular Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the N-terminus of human arginase-1 protein |
Lokalisation |
Cytoplasm, nucleus |
Arginase-1
|
501-19284 |
1 ml |
- |
RUO |
polyclonal |
- |
Host |
Rabbit |
Klon |
SP156 |
Format |
Concentrate |
Reaktivität |
BV, PG, RB |
Methode |
P |
Vorbehandlung |
EDTA |
Verdünnung |
1:100 |
Verdünnung |
Synthetic peptide derived from the C-terminus of human arginase-1 protein |
Arginase-1
|
501-4564 |
1 ml |
- |
RUO |
SP156 |
- |
Host |
Rabbit |
Klon |
EP261 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal human liver |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasmic and nuclear |
Arginase-1
|
API3058AA |
6 ml |
- |
CE/IVD |
EP261 |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
WB, P |
Vorbehandlung |
keine |
Positivkontrolle |
Herz |
Verdünnung |
5 µg/mL |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to a portion of the amino acid sequence between 300-450 of human ATG4-KLH conjugated |
ATG4B
|
601-0367 |
50 µg |
- |
RUO |
polyclonal |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
High-grade glioma. |
Verdünnung |
1:25-50 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptidefrom human ATRX protein |
Lokalisation |
Nucleus |
ATRX
|
Z2283RT |
0.1 ml |
- |
CE/IVD |
polyclonal |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
High-grade glioma. |
Verdünnung |
1:25-50 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptidefrom human ATRX protein |
Lokalisation |
Nucleus |
ATRX
|
Z2283RS |
0.5 ml |
- |
CE/IVD |
polyclonal |
- |
Host |
Mouse |
Klon |
D-5 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA Puffer, pH 8,0 |
Positivkontrolle |
Pancreas |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG2a kappa |
Verdünnung |
raised against amino acids 2193- 2492 mapping near the Cterminus of ATRX of human origin |
Lokalisation |
nuclear |
ATRX
|
MOB600 |
1 ml |
- |
CE/IVD |
D-5 |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
High-grade glioma. |
Verdünnung |
1:25-50 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptidefrom human ATRX protein |
Lokalisation |
Nucleus |
ATRX
|
Z2283RL |
1 ml |
- |
CE/IVD |
polyclonal |
- |
Host |
Mouse |
Klon |
D-5 |
Format |
ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA Puffer, pH 8,0 |
Positivkontrolle |
Pancreas |
Verdünnung |
--- |
Isotyp |
Mouse IgG2a kappa |
Verdünnung |
raised against amino acids 2193- 2492 mapping near the Cterminus of ATRX of human origin |
Lokalisation |
nuclear |
ATRX
|
PDM600 |
6 ml |
- |
CE/IVD |
D-5 |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
High-grade glioma. |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Synthetic peptidefrom human ATRX protein |
Lokalisation |
Nucleus |
ATRX
|
Z2283RP |
7 ml |
- |
CE/IVD |
polyclonal |
- |
Host |
Mouse |
Klon |
35C1 |
Format |
Purified |
Methode |
WB, IP, IF |
Isotyp |
Mouse IgG2b |
Verdünnung |
Recombinant Aurora-A |
Aurora A Kinase
|
601-0320 |
100 µg |
- |
RUO |
35C1 |
- |
Host |
Mouse |
Klon |
TLD-3H12B |
Format |
Purified |
Methode |
F, WB, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Rat microglial cells |
b2-Microglobulin
|
602-0008 |
100 µg |
- |
RUO |
TLD-3H12B |
- |
Host |
Mouse |
Klon |
B2M-01 |
Format |
Purified |
Methode |
EL, FL |
Isotyp |
Mouse IgG2a |
Verdünnung |
Beta-2-microglobulin from human urine |
b2-Microglobulin
|
602-0005 |
250 µg |
- |
RUO |
B2M-01 |
- |
Host |
Mouse |
Klon |
TLD-3H12B |
Format |
Purified |
Methode |
F, WB, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Rat microglial cells |
b2-Microglobulin
|
602-0007 |
250 µg |
- |
RUO |
TLD-3H12B |
- |
Host |
Mouse |
Klon |
2213 |
Format |
Purified |
Methode |
EL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Highly pure beta-2-microglobulin from human urine |
b2-Microglobulin
|
602-0004 |
1 mg |
- |
RUO |
2213 |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Mesothelioma, Melanoma, Normal testis |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nuclear |
BAP1
|
ACI3247A |
0.1 ml |
- |
CE/IVD |
polyclonal |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Mesothelioma, Melanoma, Normal testis |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nuclear |
BAP1
|
ACI3247B |
0.5 ml |
- |
CE/IVD |
polyclonal |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Mesothelioma, Melanoma, Normal testis |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Nuclear |
BAP1
|
API3247AA |
6 ml |
- |
CE/IVD |
polyclonal |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Mesothelioma, Melanoma, Normal testis |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Nuclear |
BAP1
|
ALI3247G7 |
7 ml |
- |
CE/IVD |
polyclonal |
- |
Host |
Mouse |
Klon |
C-4 |
Format |
ready-to-use |
Methode |
FFPE |
Vorbehandlung |
EDTA |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
--- |
Isotyp |
IgG1, kappa |
Verdünnung |
Synthetic peptide against 430-729 of human BAP1 |
Lokalisation |
nuclear and cytoplasmic |
BAP1 (BRCA1-Associated Protein 1)
|
PDM595 |
6 ml |
- |
CE/IVD |
C-4 |
- |
Host |
Rabbit |
Klon |
SP47 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from N-terminal of human Bak. |
Lokalisation |
Cytoplasm, Cell Membrane |
Bax
|
502-3470 |
0.1 ml |
- |
RUO |
SP47 |
- |
Host |
Rabbit |
Klon |
SP47 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from N-terminal of human Bak. |
Lokalisation |
Cytoplasm, Cell Membrane |
Bax
|
502-3472 |
0.5 ml |
- |
RUO |
SP47 |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from internal region of human BAX protein |
Lokalisation |
Cytoplasm, Cell Membrane |
Bax
|
502-17994 |
1 ml |
- |
RUO |
polyclonal |
- |
Host |
Rabbit |
Klon |
SP47 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from N-terminal of human Bak. |
Lokalisation |
Cytoplasm, Cell Membrane |
Bax
|
502-3474 |
1 ml |
- |
RUO |
SP47 |
- |
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from internal region of human BAX protein |
Lokalisation |
Cytoplasm, Cell Membrane |
Bax
|
502-17991 |
7 ml |
- |
RUO |
polyclonal |
- |
Host |
Mouse |
Klon |
Cu-18 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer, Lung cancer, Ovarian cancer, Endometrial cancer |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic |
BCA-225
|
ACI3241A |
0.1 ml |
- |
CE/IVD |
Cu-18 |
- |
Host |
Mouse |
Klon |
Cu-18 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma, fallopian tube, or skin. |
Verdünnung |
1:25 - 100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide |
Lokalisation |
Cytoplasm |
BCA-225
|
Z2141MT |
0.1 ml |
- |
CE/IVD |
Cu-18 |
- |
Host |
Mouse |
Klon |
Cu-18 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer, Lung cancer, Ovarian cancer, Endometrial cancer |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic |
BCA-225
|
ACI3241B |
0.5 ml |
- |
CE/IVD |
Cu-18 |
- |
Host |
Mouse |
Klon |
Cu-18 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma, fallopian tube, or skin. |
Verdünnung |
1:25 - 100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide |
Lokalisation |
Cytoplasm |
BCA-225
|
Z2141MS |
0.5 ml |
- |
CE/IVD |
Cu-18 |
- |
Host |
Mouse |
Klon |
Cu-18 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma, fallopian tube, or skin. |
Verdünnung |
1:25 - 100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide |
Lokalisation |
Cytoplasm |
BCA-225
|
Z2141ML |
1 ml |
- |
CE/IVD |
Cu-18 |
- |
Host |
Mouse |
Klon |
Cu-18 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer, Lung cancer, Ovarian cancer, Endometrial cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasmic |
BCA-225
|
API3241AA |
6 ml |
- |
CE/IVD |
Cu-18 |
- |
Host |
Mouse |
Klon |
Cu-18 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma, fallopian tube, or skin. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide |
Lokalisation |
Cytoplasm |
BCA-225
|
Z2141MP |
7 ml |
- |
CE/IVD |
Cu-18 |
- |
Host |
Mouse |
Klon |
124.0 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide, aa 41-54 (GAAPAPGIFSSQPG-Cys) of human bcl-2 protein |
Lokalisation |
Cytoplasm |
BCL-2
|
Z2022MT |
0.1 ml |
- |
CE/IVD |
124.0 |
- |
Host |
Mouse |
Klon |
124.0 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide, aa 41-54 (GAAPAPGIFSSQPG-Cys) of human bcl-2 protein |
Lokalisation |
Cytoplasm |
BCL-2
|
Z2022MS |
0.5 ml |
- |
CE/IVD |
124.0 |
- |
Host |
Mouse |
Klon |
124.0 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide, aa 41-54 (GAAPAPGIFSSQPG-Cys) of human bcl-2 protein |
Lokalisation |
Cytoplasm |
BCL-2
|
Z2022ML |
1.0 ml |
- |
CE/IVD |
124.0 |
- |
Host |
Mouse |
Klon |
124.0 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide, aa 41-54 (GAAPAPGIFSSQPG-Cys) of human bcl-2 protein |
Lokalisation |
Cytoplasm |
BCL-2
|
Z2022MP |
7 ml |
- |
CE/IVD |
124.0 |
- |
Host |
Monospecific Mouse |
Klon |
ZM22 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsi lor diffuse large B-cell lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human BCL-6 protein fragment (aa256-389) (exact sequence is proprietary) |
Lokalisation |
Nucleus |
BCL-6
|
Z2343MT |
0.1 ml |
- |
CE/IVD |
ZM22 |
- |